By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics reported after the close of the market Tuesday that its second-quarter 2012 revenues increased 22 percent year over year with molecular diagnostic revenues up 17 percent.

The Salt Lake City-based firm had total revenues of $122.8 million for the three-month period ended Dec. 31, 2011, compared to $100.4 million for the second quarter of 2011. It beat Wall Street's consensus estimate for revenues of $115.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.